August 15, 2011
Nile Therapeutics Reports 2011 Second Quarter Financial Results
SAN MATEO, Calif., Aug. 15, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a company focused on the development of novel therapeutics for cardiovascular disease, today announced its second quarter financial results for 2011.
For the three months ended June 30, 2011, Nile reported a net loss of approximately $0.9 million, or $0.03 per share, compared to a net loss of approximately $1.5 million, or $0.05 per share, during the second quarter of 2010. Weighted-average shares outstanding for the second quarter of 2011 were 35.1 million.
Net cash used in operating activities in the second quarter of 2011 was approximately $1.2 million. As of June 30, 2011, Nile had cash and cash equivalents of approximately $3.3 million compared to approximately $3.4 million as of December 31, 2010.
Update on cenderitide
Nile is developing cenderitide as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital. The program was recently granted Fast Track status by the United States Food and Drug Administration (FDA).
As of August 15, 2011, all subjects in the low-dose cohort in Part B of the study have been enrolled. In Part B of the trial, patients receive a 24-hour continuous infusion of either cenderitide or placebo, delivered through Medtronic's subcutaneous pump technology. Nile expects that enrollment of the Phase I trial will be completed in the fourth quarter of 2011.
"We congratulate our investigators and our research partners for their outstanding efforts," said Hsiao Lieu, MD, Vice President of Clinical Research at Nile. "Based on our interim analysis of the low-dose cohort, we are pleased with the pharmacokinetics, bioavailability and safety of the continuous subcutaneous infusion of cenderitide using the Medtronic pump."
About Heart Failure
Heart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. This hospitalization rate is almost double the rate seen 15 years ago, and is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $33 billion.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.
Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Summary Income Statement Data (unaudited)
Three Months Ended June 30, ------------------ 2011 2010 ---- ---- Income Grant income $- $- Collaboration income 346,000 - ------- --- Total income 346,000 - ------- --- Operating expenses: Research and development 702,930 1,055,759 General and administrative 523,305 445,448 ------- ------- Total operating expenses 1,226,235 1,501,207 --------- --------- Loss from operations (880,235) (1,501,207) Other income (expense): Interest income 1,046 6,726 Interest expense - - Other income (expense) (1,341) (40) ------ --- Total other income (expense) (295) 6,686 ---- ----- Net loss $(880,530) $(1,494,521) ========= =========== Basic and diluted loss per share $(0.03) $(0.05) ====== ====== Weighted-average common shares outstanding 35,091,653 32,285,824 ========== ==========
Period from August 1, 2005 (inception) through June 30, 2011 ----------------- Income Grant income $482,235 Collaboration income 346,000 ------- Total income 828,235 ------- Operating expenses: Research and development 27,184,202 General and administrative 15,308,014 ---------- Total operating expenses 42,492,216 ---------- Loss from operations (41,663,981) Other income (expense): Interest income 790,991 Interest expense (1,273,734) Other income (expense) 140,208 ------- Total other income (expense) (342,535) -------- Net loss $(42,006,516) ============ Basic and diluted loss per share Weighted-average common shares outstanding
Summary Balance Sheet Data (in thousands)
June 30, December 31, 2011 2010 (unaudited) Cash and cash equivalents $3,260 $3,378 Total assets $3,704 $3,666 Stockholders' equity $3,268 $2,597
SOURCE Nile Therapeutics, Inc.